Literature DB >> 3354621

Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.

R Matalon1, K Michals, D Sebesta, M Deanching, P Gashkoff, J Casanova.   

Abstract

An increased amount of N-acetylaspartic acid was found in urine and plasma of three patients, from two families, with the diagnosis of cerebral spongy degeneration (Canavan disease). Aspartoacylase was assayed in cultured skin fibroblasts from one patient of each family and a profound deficiency of this enzyme was found. Although the function of N-acetylaspartic acid is not understood, it is known to occur in high concentration in human brain. The finding of a defect in the metabolism of N-acetylaspartic acid causing progressive spongy degeneration of the brain may lead to a better understanding of the function of this amino acid derivative. The aspartoacylase assay affords a new tool for determining the diagnosis of Canavan disease. Since aspartoacylase activity was present in cultured amniotic cells and chorionic villi, it is likely that the assay for this enzyme can be used for the prenatal diagnosis of Canavan disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3354621     DOI: 10.1002/ajmg.1320290234

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  92 in total

Review 1.  Biochemistry and molecular biology of Canavan disease.

Authors:  R Matalon; K Michals-Matalon
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Prenatal diagnosis of Canavan disease.

Authors:  R Matalon; K Michals; P Gashkoff; R Kaul
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  Prenatal diagnosis of Canavan disease.

Authors:  C Jakobs; H J ten Brink; P Divry; M O Rolland
Journal:  Eur J Pediatr       Date:  1992-08       Impact factor: 3.183

4.  The impact of structural biology on neurobiology.

Authors:  Ronald E Viola
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

5.  Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.

Authors:  R Kaul; G P Gao; R Matalon; M Aloya; Q Su; M Jin; A B Johnson; R B Schutgens; J T Clarke
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

6.  Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): comparison of enzymatic and metabolite analysis.

Authors:  M J Bennett; K M Gibson; W G Sherwood; P Divry; M O Rolland; O N Elpeleg; P Rinaldo; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  SSIEM Award. Aspartoacylase deficiency: the enzyme defect in Canavan disease.

Authors:  R Matalon; R Kaul; J Casanova; K Michals; A Johnson; I Rapin; P Gashkoff; M Deanching
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

8.  The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel.

Authors:  O N Elpeleg; Y Anikster; V Barash; D Branski; A Shaag
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

9.  Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis.

Authors:  O N Elpeleg; A Shaag; Y Anikster; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

10.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.